VKTX241213C45000
- 1.20
- -3.20-72.73%
Viking Therapeutics Newsroom
Viking Therapeutics, Inc. (VKTX) Stock Moves -1.75%: What You Should Know
"Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.
Viking Engineering Laboratory Achieves ISO 17025 Accreditation
10 Health Care Stocks With Whale Alerts In Today's Session
The Zacks Analyst Blog Eli Lilly, Novo Nordisk's Amgen and Viking Therapeutics
Promising Prospects for Viking Therapeutics' VK2735 in Obesity Treatment: A Buy Rating With $125 Price Target
'ADA Advises Against Using Compounded GLP-1 RA Medications' - Medscape
After Crashing 27% in the Past Month, Is Viking Therapeutics Stock a Bargain Buy Right Now?
Corbus, Viking Initiated at Overweight by Piper Sandler
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Piper Sandler Initiates Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $74
Express News | Viking Therapeutics Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $74
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
Here's Yet Another Reason to Buy Viking Therapeutics Stock Like There's No Tomorrow
Is weight loss medication including in usa medical insurance, becoming the strongest 'roadblock' for the Trump team?
"Weight loss duo" leads significant increase.
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125
Amgen Obesity Drug Falls Short of Efficacy Expectations in Trial, Mizuho Says; Shares Decline
H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102
HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target